Fu‐Sheng Wang
Impact in
- Hepatology top 0.1%
- Hepatitis C virus research
- Infectious Diseases top 0.05%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
- Virology 55
- HIV Research and Treatment 55
- Hepatology 82
- Hepatitis C virus research 46
Fu‐Sheng Wang
289 papers receiving 19.5k citations
Hit Papers
Peers
Comparison fields: 5 of 189
- Hepatology 3.6k
- Infectious Diseases 6.9k
- Immunology 5.2k
- Neurology 3.3k
- Epidemiology 5.5k
Countries citing papers authored by Fu‐Sheng Wang
This map shows the geographic impact of Fu‐Sheng Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fu‐Sheng Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fu‐Sheng Wang more than expected).
Fields of papers citing papers by Fu‐Sheng Wang
This network shows the impact of papers produced by Fu‐Sheng Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fu‐Sheng Wang. The network helps show where Fu‐Sheng Wang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fu‐Sheng Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 8 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 5 | |
| 5 | 2024 | 2 | |
| 6 | 2023 | 3 | |
| 7 | 2023 | 3 | |
| 8 | 2023 | 8 | |
| 9 | 2023 | 4 | |
| 10 | 2023 | 1 | |
| 11 | 2023 | 3 | |
| 12 | 2021 | 10 | |
| 13 | 2021 | 10 | |
| 14 | 2020 | 24 | |
| 15 | 2020 | 83 | |
| 16 | 2020 | 3 | |
| 17 | 2016 | 42 | |
| 18 | [Cultivation and Standardized Technology Research on A New Astragalus Variety of Longqi 4]. | 2016 | 0 |
| 19 | Study on the correlation between CD4~+ cytotoxic T and course of primary hepatocellular carcinoma | 2013 | 1 |
| 20 | Evaluation on the efficacy of human umbilical cord derived-mesenchymal stem cell transplantation in liver cirrhosis patients with ascites in a prospective and control trial | 2012 | 3 |
About Fu‐Sheng Wang
Fu‐Sheng Wang is a scholar working on Virology, Hepatology, Immunology, Infectious Diseases and Epidemiology, having authored 310 papers that have together received 19.9k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (80 papers), Hepatitis B Virus Studies (76 papers), HIV Research and Treatment (55 papers), Liver Disease Diagnosis and Treatment (55 papers), Hepatitis C virus research (46 papers), COVID-19 Clinical Research Studies (35 papers), Immunotherapy and Immune Responses (34 papers) and SARS-CoV-2 and COVID-19 Research (26 papers). The work is most often cited by research in Hepatology (3.6k citations), Infectious Diseases (6.9k citations), Immunology (5.2k citations), Neurology (3.3k citations) and Epidemiology (5.5k citations). Fu‐Sheng Wang has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Chao Zhang, Lei Shi, Zheng Zhang, Lifeng Wang, Jin‐Wen Song, Jingmin Zhao, Zhe Xu, Peng Zhao, Peng Xia and Hongxia Liu. Their work appears in journals such as Hepatology International, Frontiers in Immunology, Hepatology, Cellular and Molecular Immunology and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.